Polyrizon raises $3.5 million through share and warrant offering

Polyrizon Ltd. (NASDAQ: PLRZ) announced it has entered into definitive agreements with a single institutional investor for a registered direct offering and concurrent private placement expected to generate approximately $3.5 million in gross proceeds.

The biotechnology company, which develops intranasal protective solutions and is in pre-clinical stage, will sell 388,888 units at $9.00 per unit. Each unit consists of one ordinary share or one pre-funded warrant to purchase one ordinary share, plus one common warrant to purchase one ordinary share.

The registered direct offering includes 87,777 ordinary shares and 190,000 pre-funded warrants. The concurrent private placement involves 111,111 pre-funded warrants and 388,888 common warrants. Pre-funded warrants are immediately exercisable and may be exercised until exercised in full. Common warrants carry an exercise price of $9.00 per share.

The transactions are expected to close on or about April 8, 2026, subject to customary closing conditions. Polyrizon plans to use the net proceeds along with existing cash for general corporate purposes and working capital.

Following completion of the offering, the company will have 2,083,939 ordinary shares issued and outstanding, assuming exercise of all pre-funded warrants issued in the offering.

You May Also Be Interested In

• Nuvectis Pharma (NVCT) files $200M mixed shelf
• Boeing names Ryan Shedd as new SVP and controller
• ZeroStack (ZSTK) files for 54.61M share offering by selling stockholders